IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10369148 B1

PDFFull Text
Date of Patent:
Aug. 06, 2019

Filed:

Dec. 01, 2016

2,4-pyrimidinediamine compounds and their uses

Applicant:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Rajinder Singh, Belmont, CA (US);

Ankush Argade, Foster City, CA (US);

Donald G. Payan, Hillsborough, CA (US);

Susan Molineaux, San Francisco, CA (US);

Sacha J. Holland, San Francisco, CA (US);

Jeffrey Clough, Redwood City, CA (US);

Holger Keim, Newbury Park, CA (US);

Somasekhar Bhamidipati, Foster City, CA (US);

Catherine Sylvain, San Mateo, CA (US);

Hui Li, Santa Clara, CA (US);

Alexander B. Rossi, Reedsport, OR (US);

Assignee:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorneys:

Travis Young

Klarquist Sparkman, LLP

Primary Examiner:

Deepak R Rao

Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61K 31/519 (2006.01); C07D 239/48 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/5383 (2006.01); A61K 31/551 (2006.01); A61K 45/06 (2006.01); C07D 498/04 (2006.01); C07D 265/36 (2006.01); A61K 31/5395 (2006.01); C07D 495/04 (2006.01); C07F 5/02 (2006.01); C07D 498/14 (2006.01); C07D 407/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); C07D 239/48 (2013.01); C07D 265/36 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01); C07D 498/14 (2013.01); C07F 5/027 (2013.01);
Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Find Patent Forward Citations

Loading…